---
schema_version: "secwatch.filing_event.v1"
accession: "0001214659-23-000871"
form_type: "8-K"
ticker: "ALZN"
cik: "0001677077"
company_name: "Alzamend Neuro, Inc."
filed_at: "2023-01-20T23:59:59+00:00"
generated_at: "2026-06-20T12:33:15.304554+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "low"
source: SEC EDGAR
---

# Alzamend Neuro updates corporate presentation; no material new details disclosed

## Summary
- Alzamend Neuro refreshed its investor presentation for meetings with investors and analysts.
- Presentation covers the company's pipeline for Alzheimer's and psychiatric disorders.
- No financial results, guidance, or specific clinical milestones were reported in the filing.
- The update is a routine disclosure with no identified material changes to the company's strategy.

## SEC filing metadata
- accession: 0001214659-23-000871
- form_type: 8-K
- ticker: ALZN
- cik: 0001677077
- company_name: Alzamend Neuro, Inc.
- filed_at: 2023-01-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1677077/000121465923000871/0001214659-23-000871-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1677077/000121465923000871/r1192328k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001214659-23-000871
- JSON: https://secwatch.observer/filing/0001214659-23-000871.json
- Plain text: https://secwatch.observer/filing/0001214659-23-000871.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.